Navigation Links
Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
Date:5/9/2008

Boosts Cytopia's development of early pipeline cancer drug candidates

MELBOURNE, Australia, May 9 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of targeted therapeutics that is one of the fastest growing segments of the cancer drug market.

Cytopia will retain an option over exclusive commercialization rights for any drug candidates delivered by the collaboration. Should Cytopia choose not to exercise this option, Cancer Therapeutics may proceed with commercialization activities. In the event that all milestones to registration are successfully achieved, both Cancer Therapeutics and Cytopia will share in any partnering revenues, as well as royalty payments from a marketed drug.

Andrew Macdonald, CEO of Cytopia said, "Cytopia's drug discovery engine has generated many opportunities for novel cancer therapies and this innovative partnership gives us the freedom to focus investment on our later stage pipeline while still allowing our very early pipeline to move forward."

"Most importantly, the agreement leaves us with an option to capture the value upside for our investors if a new cancer drug is taken to market."

Under the terms of the collaboration, Cytopia has out-licensed specific proprietary technology to Cancer Therapeutics for an undisclosed kinase enzyme target with potential for treating metastatic cancers. Development of an inhibitor of this particular kinase could have blockbuster potential in the cancer market. Under the project plan,

Cancer Therapeutics will conduct and fund further development of the Cytopia compounds for at least two years. Cancer Therapeutics is a company, formed under the Australian Commonwealth Government's CRC scheme, to discover and develop new
'/>"/>

SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... NEW YORK , Aug. 28, 2014 /PRNewswire/ ... report is available in its catalogue: ... http://www.reportlinker.com/p02343464/North-America-Laparoscopes-Market-Outlook-to-2020.html North ... GlobalData,s new report, "North America Laparoscopes Market ... the North America Laparoscopes market. The report provides ...
(Date:8/28/2014)... -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – ... - http://photos.prnewswire.com/prnh/20140828/140879 ) The ... Poland " an essential source of information and ... and provides insights into the demographic, regulatory, reimbursement ... provides valuable insights into the trends and segmentation ...
(Date:8/28/2014)... , Aug. 28, 2014 Tianyin ... ), a pharmaceutical company that specializes in patented ... and active pharmaceutical ingredients (API) today updates the ... Qionglai Facility (QLF). The Company ... (GMP) dataset for China Food & Drug Administration,s ...
Breaking Medicine Technology:North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2
... Some of the world,s largest pharmaceutical firms announced this ... in order to slash costs and keep investors happy, exposing ... AstraZeneca were the first to announce further job cuts with ... has already seen an extraordinary amount of job cuts over ...
... Md., Feb. 29, 2012  MedImmune today announced that ... approved FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) for ... early in the second quarter of last year.  ... approved by the FDA. All other ...
Cached Medicine Technology:Job Cuts from Major Pharmaceutical Firms Results in Tougher Competition, Says Advance Recruitment 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 2MedImmune Announces FDA Approval of First Four-strain Flu Vaccine, FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) 3
(Date:8/29/2014)... The University of Houston Graduate College of Social Work is ... $1.25 million grant from the National Institute of Drug Abuse ... the long-term use and health consequences of heroin use. Additionally, ... support future research endeavors. , Heroin use has ... from prescription pain medication abuse to the cheaper and more ...
(Date:8/29/2014)... Lincoln, R.I. (PRWEB) August 29, 2014 A home ... can crop up if unaddressed. That’s why Amica Insurance is sharing ... The National Safety Council suggests taking the following safety measures: , ... and disinfectants – in their original containers, and keep them away ... on a wall bracket near an exit. , Bathroom ...
(Date:8/29/2014)... well-studied neuroregenerative effect, stimulating neurite extension in ... vitro, and enhancing nerve regeneration following nerve ... of FK506 to stimulate nerve regeneration is ... failure and hypertension, and its considerable cost. ... with other drugs reportedly cause life-threatening infections. ...
(Date:8/29/2014)... As a chiropractic physician and medical doctor an ... direct connection between the condition of the feet and ... shoe inserts and orthotics weren’t satisfying my patients, I ... said. , Customizable to a user’s needs, the patent-pending ... in order to help prevent pain in the foot, ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The main ... the Middle East and North Africa originated in ... studied so-called community-acquired methicillin-resistant Staphylococcus aureus ... have not recently been hospitalized. These infections typically ... person-to-person contact or through touching contaminated objects such ...
Breaking Medicine News(10 mins):Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Improve Home Safety with Tips from Amica Insurance 2Health News: European MRSA Originated in Sub-Saharan Africa, Study Finds 2
... (OTCBB: GVBP.OB) - GENova Biotherapeutics Inc. ("GENova") today announced ... PLC and unconditionally retract the announcement made earlier this ... Jensen, Chief Science Officer of Bridge BioResearch PLC, will ... , , About GENova Biotherapeutics Inc. , ...
... MISSION VIEJO, Calif., Sept. 18 The Ensign Group, Inc. ... group of skilled nursing, rehabilitative care services and assisted living companies, ... cash dividend of $0.045 per share of Ensign common stock, payable ... of September 30, 2009. Ensign has been a dividend-paying company since ...
... - revenues increase by 21% over ... figures are in Canadian dollars unless otherwise noted), , ... Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today ... 30, 2009. , "We had a very successful year in ...
... HAYWARD, Calif., Sept. 18 Solta Medical, Inc. (Nasdaq: ... market, today announced that it will present at the Maxim Group ... the Grand Hyatt New York Hotel in New York, NY. ... September 29, 2009. Stephen J. Fanning, Chairman, President and Chief ...
... SAN CARLOS, Calif., Sept. 18 Nektar Therapeutics (Nasdaq: ... Global Life Sciences Conference in New York at the Grand Hyatt Hotel ... , The presentation will be accessible via a Webcast through ... Nektar website: http://www.nektar.com . This Webcast will be available ...
... be a nasal spray, followed shortly by injectable one: CDC ... doses of the H1N1 swine flu vaccine will start shipping ... U.S. health officials said Friday. , These first 3.4 million ... FluMist. , "There is a good antibody response to the ...
Cached Medicine News:Health News:Bioniche Reports Fiscal 2009 Year-End Results 2Health News:Bioniche Reports Fiscal 2009 Year-End Results 3Health News:Bioniche Reports Fiscal 2009 Year-End Results 4Health News:Bioniche Reports Fiscal 2009 Year-End Results 5Health News:Bioniche Reports Fiscal 2009 Year-End Results 6Health News:Bioniche Reports Fiscal 2009 Year-End Results 7Health News:Bioniche Reports Fiscal 2009 Year-End Results 8Health News:Bioniche Reports Fiscal 2009 Year-End Results 9Health News:Bioniche Reports Fiscal 2009 Year-End Results 10Health News:Bioniche Reports Fiscal 2009 Year-End Results 11Health News:Bioniche Reports Fiscal 2009 Year-End Results 12Health News:Bioniche Reports Fiscal 2009 Year-End Results 13Health News:Bioniche Reports Fiscal 2009 Year-End Results 14Health News:Bioniche Reports Fiscal 2009 Year-End Results 15Health News:Solta Medical to Present at the Maxim Group Growth Conference 2Health News:Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 2Health News:1st Doses of Swine Flu Vaccine Set for Early October 3Health News:1st Doses of Swine Flu Vaccine Set for Early October 4
... These specialty Eraser instruments have been ... with the right tool for situations ... a series of 25 gauge intraocular, ... discrete treatment of target tissues for ...
... to over 2,000 medical clinics nation wide, ... in mind, ChartingPlus relies heavily on a ... to improve documentation quality and increase productivity ... medical content is specific to your medical ...
Transfer your exams to AltaPoint with our EMR Exam Word Lists. Document systems as normal and annotate exceptions to the systems in the exam. AltaPoint EMR is configured to allow a specialty to cust...
... Pro Software developed a touchscreen EHR and ... While a user can choose to use ... to maintain eye contact while recording encounter ... Pro EHR also runs on a pen ...
Medicine Products: